Erasca jumps as ERAS-0015 clinical momentum and fresh price-target hikes drive buying
Erasca shares rose about 4% to $19.20 as biotech traders extended a momentum run tied to enthusiasm for ERAS-0015, its pan-RAS molecular glue. Recent catalysts include early Phase 1 response disclosures and a wave of higher analyst price targets into a first-half 2026 data update window.
1) What’s moving ERAS today
Erasca (ERAS) traded higher as investors continued to price in optimism around ERAS-0015, the company’s lead pan-RAS molecular glue program, ahead of a planned first-half 2026 Phase 1 monotherapy update. The stock has also been supported by recent analyst reiterations and price-target increases that framed ERAS-0015 as a potentially differentiated entrant in a high-interest RAS oncology landscape.
2) The underlying catalyst: early clinical signals and near-term milestones
In January 2026, Erasca disclosed encouraging early dose-escalation activity for ERAS-0015, including confirmed and unconfirmed partial responses across multiple tumor types and RAS mutations, alongside favorable tolerability and pharmacokinetics. Management also pointed to faster-than-expected enrollment and reiterated its timeline for initial Phase 1 monotherapy data in the first half of 2026, keeping the market focused on a near-term clinical update as the next major inflection point.
3) Sentiment booster: recent analyst target changes and rivalry framing
Sell-side commentary in March and April 2026 has emphasized competitive benchmarking versus other RAS-pathway programs and framed the upcoming ERAS-0015 readout as a key catalyst. Recent notes have highlighted expectations for a 2026 data presentation window and included multiple bullish targets (including $18–$21 in recent coverage), reinforcing speculative interest even on days without a new company press release.